Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...
Business Insider1mon
Immuneering to present data from Phase 2a trial of IMM-1-104 in early January
PD and safety data from the Phase 1 portion of the company’s Phase 1/2a trial of IMM-6-415. Details of how to access the Investor Event will be provided in due course. Published first on TheFly ...